Search companies

Live

Tuesday, 17 November 2026 · 586 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Nexalis Ends LFO Facility, Replaces 38 Million Options With 15 Million

NX1: $0.009 +0.00% · MC: $2M

Nexalis Therapeutics says its LFO funding facility has been terminated by mutual agreement, with no repayment due and the lender’s security released; 38 million existing options have lapsed and the company proposes issuing 15 million replacement options to settle funding received. September-quarter cash fell to approximately $371,000 from $790,000 at the previous quarter-end, while the company says it is working to arrange forward funding against its research tax incentive and is seeking other funding for clinical trials.

Source announcements: 2026-10-30 08:52 to 2026-10-30 09:09 Sydney time
Story updated 2026-10-30 09:11 Sydney time
SourcesNotification of cessation of securities - NX1Sep26 Appendix 4C Cash Flow ReportSep26 Quarterly Activities ReportProposed issue of securities - NX1
Comments